Stock Detail
CORESITE REALTY CORPORATION
Drugs
COR @ Yahoo Finance | COR Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $16.40 | $16.59 | $-0.14 | -0.85% | 0.52 | $16.54 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $16.36 | $16.15 | 76,699 | 325.52M | 126,055.67 | 12.06 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 16.82 | 16.61 | 16.38 | 16.17 | 15.94 |
Stock Profile
Cortex Pharmaceuticals, Inc. engages in the discovery and development of pharmaceuticals for the treatment of neurological and psychiatric disorders. The company develops AMPAKINE drugs for the treatment of alzheimer's disease, mild cognitive impairment, schizophrenia, depression, narcolepsy, hyperactivity disorder, autism, fragile X, stroke, traumatic brain and spinal cord injury, parkinson's disease, and other neurological diseases. Its lead product includes AMPAKINE CX717, which has completed phase II clinical trial. The company has research collaboration agreements with N.V. Organon, which grants Organon rights to develop and commercialize the company's AMPAKINE technology for the treatment of schizophrenia and depression; and Les Laboratoires Servier that would allow Servier to develop and commercialize the company's AMPAKINE technology as a treatment for memory impairment associated with aging and neurodegenerative diseases. Cortex Pharmaceuticals was founded in 1987 and is based in Irvine, California.